Loading…
← CockpitCompetitor Analysis › 7871.TWO Elixiron Immunotherapeutics (Cayman) LimitedOpen in the cockpit ↗

Elixiron Immunotherapeutics (Cayman) Limited7871.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Pharmaceuticals: Major
Momentum leader 92
Mkt cap
$412M
US dollars, full cap
$/day
$2.10M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-34.9 pp
WACC 8.9%
Hurdle
n/a
no reverse DCF
Close · TWDNT$113.50
1D-3.8%
1W-0.9%
1M-17.1%
3M-1.3%
6M+64.2%
YTDn/a
1Yn/a
ATR %8.6%
52w lowhigh38.6% off high

What Elixiron Immunotherapeutics (Cayman) does

Employees: 30

Elixiron Immunotherapeutics (Cayman) at a glance

Size Elixiron Immunotherapeutics (Cayman) (7871.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $412M, the 496th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$113.50 on 18 Nov 2026.

Performance Over six months the shares gained 64.2%, against -21.3% for the median peer and -3.4% for the Taiwan market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 6,162.4% over the last twelve months (peer median +3.4%); the operating margin is -194.2% (peer median 1.9%).

Valuation It trades at 119.7× enterprise value to sales against a peer median of 3.3× (4th most expensive of 19).

Capital Return on invested capital runs 34.9 points below its cost of capital (8.9% WACC).

Relative performance

10020021 May 202621 Aug 202618 Nov 20267871.TWO 164Peer median 81
Six months, rebased to 100: Elixiron Immunotherapeutics (Cayman) against the median of its 20 peers (local-currency closes).

Elixiron Immunotherapeutics (Cayman) financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
RevenueNT$113MNT$50.3MNT$803,000NT$25.7M
Revenue growth—+6,162%-97%—
Gross profitNT$104MNT$40.8M-NT$7.18MNT$19.7M
EBITDA-NT$211M-NT$187M-NT$209M-NT$117M
Net income-NT$156M-NT$1.11B-NT$440MNT$268M
Free cash flow-NT$156M-NT$132M-NT$250M-NT$106M
Capital expenditure-NT$57,000NT$5.50MNT$9.97MNT$217,000
Total debtn/aNT$24.9MNT$1.38BNT$778M

Quarterly statements and history in the cockpit →

Elixiron Immunotherapeutics (Cayman) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%RZLTCTMX0028646535000931002728002581603139TVGN0010606010894114048410300636OVIDZOTA600613002923PHAT219A7871.TWO6-month return →1-month return →
Up and to the right = strong over both horizons. Elixiron Immunotherapeutics (Cayman) is the large dot.

Fundamentals: revenue growth against valuation

0%+2,000%+4,000%+6,000%0×200×400×CTMX0028646535048410OVID219A7871.TWORevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Elixiron Immunotherapeutics (Cayman) is the large dot.

Elixiron Immunotherapeutics (Cayman) competitors and peer comparison

How Elixiron Immunotherapeutics (Cayman) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Elixiron Immunotherapeutics (Cayman) against its 20 peers (data as of 18 Nov 2026)
Measure7871.TWOPeer medianRank in peer set
1-month return-17.1%-9.8%5th lowest of 21
6-month return+64.2%-21.3%highest of 21
Distance from 52-week high-38.6%-48.8%7th highest of 21
Revenue growth (TTM)+6,162.4%+3.4%highest of 19
Operating margin-194.2%1.9%5th lowest of 19
EV / Sales119.7×3.3×4th most expensive of 19
ROIC minus cost of capital-34.9 pp-4.8 pp4th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Elixiron Immunotherapeutics (Cayman) 7871.TWOTaiwan$412M+64%+6,162%-194%119.7×n/an/a
Rezolute RZLTUnited States$411M+32%n/an/an/an/an/a
CytomX Therapeutics CTMXUnited States$410M-49%-88%-676%4.7×n/an/a
Shaanxi Panlong Pharmaceutical 002864.SZChina$407M-15%-16%7%1.7×-3.2%+11.2%
Lumosa Therapeutics 6535.TWOTaiwan$406M-37%-25%-803%399.1×n/an/a
Beijing Centergate Technologies (Holding) 000931.SZChina$406M-18%-16%2%1.9×9.2%+6.7%
Teyi Pharmaceutical 002728.SZChina$419M-12%-7%7%3.2×24.4%+8.0%
Shandong Sinobioway Biomedicine 002581.SZChina$405M-24%+91%-65%7.9×n/an/a
Shaanxi Kanghui Pharmaceutical Co 603139.SSChina$421M-31%+1%-39%7.1×n/an/a
Tevogen TVGNUnited States$422M-38%n/an/an/an/an/a
JW Pharmaceutical 001060.KSSouth Korea$423M-26%+9%13%0.7×-15.4%+7.2%
Beijing Foyou Pharma 601089.SSChina$423M-27%+5%10%0.2×n/an/a
Synmosa Biopharma 4114.TWOTaiwan$423M-1%+21%10%2.2×5.4%+15.3%
Hyundai Bioscience 048410.KSSouth Korea$424M-50%+78%-580%164.0×n/an/a
Jiangxi Synergy Pharmaceutical 300636.SZChina$398M-13%-3%2%3.4×14.9%+13.7%
Ovid Therapeutics OVIDUnited States$427M-5%-78%-4,700%208.3×n/an/a
Zota Health Care ZOTA.NSIndia$427M+9%+69%-16%6.2×n/an/a
Shanghai Shenqi Pharmaceutical Investment Management 600613.SSChina$427M+4%-4%3%1.2×10.6%+1.4%
Zhuhai Rundu Pharmaceutical 002923.SZChina$430M-30%+14%5%2.2×1.4%-1.3%
Phathom Pharmaceuticals PHATUnited States$431M-55%+87%-9%2.9×n/an/a
Heartseed 219A.TJapan$392M+53%+197%9%21.9×46.5%+73.2%

Questions

Which companies are Elixiron Immunotherapeutics (Cayman)'s closest peers?
The cockpit's peer set: Rezolute (RZLT), CytomX Therapeutics (CTMX), Shaanxi Panlong Pharmaceutical (002864.SZ), Lumosa Therapeutics (6535.TWO), Beijing Centergate Technologies (Holding) (000931.SZ), Teyi Pharmaceutical (002728.SZ), Shandong Sinobioway Biomedicine (002581.SZ), Shaanxi Kanghui Pharmaceutical Co (603139.SS).
Is Elixiron Immunotherapeutics (Cayman) expensive compared with its peers?
On ev / sales it trades at 119.7× against a peer median of 3.3×, 4th most expensive of 19 in its peer set.
How has Elixiron Immunotherapeutics (Cayman) stock performed?
Over six months to 18 Nov 2026 the shares returned +64.2% against -21.3% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.